- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05508230
Evaluation of Cutaneous Acceptability and Perceived Effectiveness of a Nasal Spray (Health Care Products)
July 20, 2023 updated by: Herbarium Laboratorio Botanico Ltda
Clinical Study to Evaluate the Safety of the Investigational Product NASAL SPRAY Through of Assessments of Cutaneous Acceptability and Perceived Efficacy Under Normal Conditions of Use
This is a clinical study for health care product safety assessment.
The research is going to conducted with 45 subjects, aged 18 to 70 years, women users of the product category, regardless of color/race, ethnicity, sexual orientation, classes and social groups and who must present all the other characteristics of the inclusion criteria and no exclusion characteristics.
The product is applied under real conditions of use, in a panel of survey participants corresponding to the target consumers.
Medical evaluation will be available throughout the study to assess possible adverse events.
The main of the study is to observe the effects of the application of the product on the skin and prove the absence of irritability and/or allergy and perceived acceptability.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13041-315
- Kosmoscience Ciência e Tecnologia Cosmética Ltda
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Phototype (Fitzpatrick): I to VI.
- User of the same product category.
- Have intact skin in the study region.
- Agree to adhere to the study procedures and requirements: study time, returns (after 28 days) to the laboratory to perform the study procedures, home use of the investigational product, filling in the use diary, not changing facial cosmetic habits during the period of study.
- Agree not to perform facial aesthetic dermatological treatments until the end of the study (28 days), such as: peelings, laser, fillers, use of any facial cosmetics.
- Agree to adhere to the requirements of the study in the fight against the COVID-19 pandemic, through preventive measures: use a mask according to WHO guidelines; use the mask while traveling to the research center and during the study procedures; maintain social distancing; wash hands frequently with soap and/or alcohol gel and go to the research center only at scheduled times to avoid agglomerations.
- Signing of the Free and Informed Consent Term (FICT).
Exclusion Criteria:
- Pregnant or lactating women.
- Skin tags in the experimental area that interfere in the assessment of possible skin reactions (pigmentation disorders, vascular malformations, scars, increased hairiness, large amounts of freckles and warts, sunburn).
- Presence of active dermatoses or skin lesions (local and/or disseminated) in the study region.
- Carriers of corneal ulcerations, keratoconus, blepharitis, meibomitis, pterygium, chemosis, hyperemia or other active eye diseases of moderate or severe intensity.
- History of ineffectiveness, allergic reactions, irritation or intense discomfort sensation to topical products: cosmetics or medicines.
- Expected vaccination during the study or up to 3 weeks before the study;
- History of pathologies aggravated or triggered by ultraviolet radiation.
- Use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study.
- Facial aesthetic or dermatological treatment up to 4 weeks before the study.
- Hormonal treatments not stable in the last 3 months.
- Hyperpigmentation associated with the use of drugs such as tetracycline, phenothiazides, or amiodarone.
- Hyperpigmentation associated with photosensitivity.
- Actinic lichen planus;
- People directly involved in carrying out this study and their families.
- Be participating in another study.
- History of non-adherence or unwillingness to adhere to the study protocol.
- Intense sun exposure or tanning session up to 15 days before the initial assessment;
- Any condition not mentioned above that, in the opinion of the investigator, could compromise the evaluation of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
|
Health care product - nasal application
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erythema degree or absence
Time Frame: 28 days
|
Erythema evaluation according to International Contact Dermatitis Research Group
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2023
Primary Completion (Actual)
June 12, 2023
Study Completion (Actual)
June 12, 2023
Study Registration Dates
First Submitted
August 18, 2022
First Submitted That Met QC Criteria
August 18, 2022
First Posted (Actual)
August 19, 2022
Study Record Updates
Last Update Posted (Actual)
July 21, 2023
Last Update Submitted That Met QC Criteria
July 20, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HB2053-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acceptance, Social
-
Children's Hospital of PhiladelphiaNoble Medical, LLCCompletedHealth Behavior | Human Papillomavirus | Acceptance Processes | Social Acceptance | Vaccine AcceptanceUnited States
-
Martin-Luther-Universität Halle-WittenbergNot yet recruiting
-
Tristen InagakiCompleted
-
Newcastle UniversityUniversity of Bristol; University of Liverpool; University of AberdeenUnknownAcceptance, SocialUnited Kingdom
-
Children's Hospital Los AngelesCompletedParenting | Health Behavior | Social Acceptance
-
Chinese University of Hong KongCompletedDisability Physical | Respect | Social AcceptanceHong Kong
-
Islamia University of BahawalpurCompleted
-
University of PittsburghNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Drinking | Depressive Symptoms | Bullying | Social AcceptanceUnited States
-
Fudan UniversityMerck Sharp & Dohme LLCWithdrawnData Collection | Machine Learning | Patient Acceptance of Health Care | Vaccination Refusal | Internet-Based Intervention | Immunization Programs | Information Dissemination | Social Medium
-
Yale UniversityCompletedDepression | Stress | Burnout | Compassion | Anxiety | Loneliness | Emotion Regulation | Social AcceptanceUnited States
Clinical Trials on Hyaluronic Nasal Spray
-
Herbarium Laboratorio Botanico LtdaCompletedSensitivity, ContactBrazil
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Viiral Nordic ABCompleted
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
P & B GroupMediAxe CROCompletedAllergic RhinitisFrance